中国的Harbor BioMed，Kelun与PD-L1达成了价值高达3.5亿美元的交易

StephenW

China’s Harbour BioMed, Kelun ink a PD-L1 deal worth up to $350M
by Amirah Al Idrus | Aug 20, 2018 10:55am
The PD-1/PD-L1 field is already crowded, with several drugs already on the market, and several more in development. (Pixabay)


Harbour BioMed licensed a midphase PD-L1 antibody from Kelun Biotech for development and commercialization outside of Greater China. Kelun stands to earn up to $350 million, but the partners did not specify how much the deal was worth upfront.

The antibody in question, A167, is currently in phase 1 and phase 2 trials in China for lymphoma and solid tumors. Harbour and Kelun will share data as they develop the asset as a monotherapy and in combination with other agents.

“We are delighted to advance A167 globally and work closely with Kelun-Biotech to achieve its therapeutic potential,” said Harbour CEO Jingsong Wang, M.D., Ph.D. “We plan to conduct A167-based combination trials globally by ourselves, including with innovative compounds we are developing, or in collaboration with our partners, to find better therapeutic options against a wide range of tumor types.”

The PD-L1 partnership is the second deal Harbour and Kelun struck this year, but is the former’s first global development alliance. Under their first collaboration, the companies agreed to co-discover, co-develop and commercialize antibodies against innovative targets, based on Harbour’s fully human antibody discovery platforms.

“[The deal] is an important step that accelerates our plan to build a highly innovative, clinical-stage portfolio for worldwide markets,” Wang said in the statement.

Shanghai-based Harbour BioMed moved in this plan in 2016, when it acquired Harbor Antibodies for an undisclosed amount, gaining a business base in Cambridge, Massachusetts, and an antibody platform development center in the Netherlands in the process.

It’s no secret that Harbour and Kelun will be playing catch-up in a field that already has five PD-1/PD-L1 meds on the market—Bristol-Myers Squibb and Merck’s blockbusters, Opdivo and Keytruda, approved for a clutch of indications, as well as PD-L1 drugs from Roche, AstraZeneca and tandem Merck KGaA/Pfizer. But an emerging school of thought that differentiates between PD-1 and PD-L1 drugs rather than grouping them all together suggests that there is room for another player in the crowded space.

StephenW

中国的Harbor BioMed，Kelun与PD-L1达成了价值高达3.5亿美元的交易
作者：Amirah Al Idrus | 2018年8月20日上午10:55
PD-1 / PD-L1领域已经拥挤，市场上已有几种药物，还有几种正在开发中。 （Pixabay）


Harbor BioMed公司从Kelun Biotech获得了中期PD-L1抗体，用于大中华区以外的开发和商业化。 Kelun的收入高达3.5亿美元，但合作伙伴没有具体说明该交易的价值。

所述抗体A167目前正在中国进行淋巴瘤和实体瘤的1期和2期试验。 Harbour和Kelun将共同开发资产作为单一疗法并与其他代理商合并。

“我们很高兴能在全球范围内推进A167，并与Kelun-Biotech密切合作，以实现其治疗潜力，”Harbour首席执行官王劲松博士说。 “我们计划在全球范围内开展基于A167的联合试验，包括我们正在开发的创新化合物，或与我们的合作伙伴合作，以找到针对多种肿瘤类型的更好的治疗选择。”

PD-L1合作伙伴关系是今年Harbour和Kelun达成的第二笔交易，但它是前者的第一个全球发展联盟。在他们的第一次合作中，两家公司同意基于Harbor的完全人类抗体发现平台共同发现，共同开发和商业化针对创新目标的抗体。

“[这笔交易]是加快我们为全球市场建立高度创新的临床阶段投资组合计划的重要一步，”王在声明中说。

总部位于上海的Harbor BioMed于2016年推出此计划，当时收购Harbor Antibodies的金额未公开，在马萨诸塞州剑桥获得业务基地，并在此过程中在荷兰建立抗体平台开发中心。

众所周知，Harbour和Kelun将在市场上已经有五种PD-1 / PD-L1药物进行追赶 - Bristol-Myers Squibb和Merck的大片，Opdivo和Keytruda，获准用于一系列适应症，以及来自Roche，AstraZeneca和Tandem Merck KGaA / Pfizer的PD-L1药物。但是，一种新兴的思想学派区分PD-1和PD-L1药物，而不是将它们全部组合在一起，这表明在拥挤的空间中有另一个玩家的空间。